Bookmark
Forward
QuickView for activated factor vii (compound)
DrugBank
Identification
| Name: | Factor VIIa |
|---|---|
| Name (isomeric): | DB00036 |
| Drug Type: | biotech |
| Description: | Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation. |
| Synonyms: |
Serum prothrombin conversion accelerator; Proconvertin; Coagulation factor VII precursor; Eptacog alfa; SPCA
|
| Brand: | NovoSeven (Novo Nordisk) |
| Category: | Coagulants, Thrombotic Agents |
| CAS number: | 9001-25-6 |
Pharmacology
| Indication: | For treatment of hemorrhagic complications in hemophilia A and B |
|---|---|
| Pharmacology: |
Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of ...
show more » |
| Mechanism of Action: | NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin. |
| Clearance: | 33 - 37 mL/h x kg [healthy] 1375 +/- 396 mL/hr [severe hemophilia A male children] 57.3 +/- 9.5 mL/hr/kg [severe hemophilia A male children] 2767 +/- 385 mL/hr [severe hemophilia A men] 37.6 +/- 13.1 mL/hr/kg [severe hemophilia A men] |
| Affected organisms: | Humans and other mammals |
Targets
